Stock drama, cancer vaccine success, and new science — highlights from AACR
There was some drama at the American Association for Cancer Research annual meeting: stocks crashed, companies debuted new compounds and trial results, and a blood cancer mystery inched closer to…
ORLANDO, Fla. — There was some drama at the American Association for Cancer Research annual meeting: stocks crashed, companies debuted new compounds and trial results, and a blood cancer mystery inched closer to being solved. If you missed the conference here this past week, here are some highlights.
Moderna and Merck showed the first randomized clinical evidence that their melanoma vaccine mRNA-4157, in combination with pembrolizumab, can reduce the risk of relapse for patients, compared to pembrolizumab alone.
What's Your Reaction?
